

CHECKPOINT

NEWSLETTER FROM HEMCHECK SWEDEN AB

MAY 2017

Here is the first newsletter from hemCheck!

Checkpoint will be published a few times a year to provide current information about the company and our development projects. Please visit our web site, www.hemcheck.com, and click on the "subscribe" link in order to get notifications of news from hemCheck.



Annelie Brolinson, CEO

Helge improves care and reduces workload

What is your experience of Helge?

Johan Burnett came in contact with Helge for the first time a year ago, when its prototype was being tested in the Emergency Department at Karlstad Central Hospital. Today he uses Helge on a daily basis, as he is participating in user tests that hemCheck is performing at the hospital.

– I use Helge when I take blood samples from a venous catheter, a PVC. In my experience, it doesn't delay my work. I continue with blood sampling while the point of care test is working.

In what situations is Helge useful to you?

– Before Helge we chanced it when we sent samples for analysis, not knowing if they were hemolyzed. I don't have to do that anymore. If I'm sitting with the blood samples in my hand, why wouldn't I test them? Great conse-

quences can be prevented with a simple measure. In my experience, the PVC is the main cause of hemolysis, therefore I'll always use Helge when drawing blood from a PVC. When I draw blood from a catheter with normal flow and it turns out to be hemolyzed I get irritated. With Helge I can check it immediately and find out if it will be able to provide accurate test results.

What's good about Helge is that it's so simple. In 20 seconds I know if I will get an answer from the laboratory within the next hour. If I don't use Helge, it may result in the patient having to wait another hour.

I can't see any disadvantages with a product like Helge. We often get hemolyzed samples when we draw blood from a PVC, or in patients who are difficult to stick and when blood flow is slow.

I don't want hemolysis; it negatively affects patient flow when doctors have to wait for test results. We shouldn't have to retake tests.

Will you use Helge in the future?


– Yes, always. I will test blood samples every time if Helge is available. I want to reduce patient suffering due to hemolysis as much as possible. We can lower the number of sticks, reduce waiting times, speed up diagnosis and achieve a better patient flow in the ER.

Previously, when I really needed a test result, I stuck the patient twice. Once to insert the PVC and once for a regular blood sample with a straight needle. Now, with Helge, I can use the PVC for the blood sample, and check the sample for hemolysis. I always use Helge on patients that are difficult to stick. I will use Helge every time I take blood samples from a PVC, if it is available after the trial.

**Hemcheck
Sweden AB
(publ)**

Karlstads Universitet
Biomedicin
Universitetsgatan 2,
S-651 88 Karlstad, Sweden
info@hemcheck.com
www.hemcheck.com

HEM CHECK™



Hemolysis means rupturing of red blood cells.

Peripheral venous catheter, catheter (PVC) is a thin catheter placed into a peripheral vein in order to gain access to the blood stream. Inserting a PVC is a common procedure with the purpose of administering medication, nutrition or fluids. Upon insertion, the line can be used to draw blood. blodprovstagning.

Johan Burnett is a registered nurse with experience from emergency medicine. Johan is currently working in the Emergency Department at Karlstad Central Hospital, where he is participating in clinical trials using Helge.

Digital reader takes shape

hemCheck is developing a product concept, Helge, which consists of a disposable point of care test and a digital reader.

Extensive user tests of the point of care test were initiated during 2016 in order to document the product's user friendliness and performance. This work is ongoing and will soon also include the digital reader. The disposable test and reader will be completed during 2017 in order for the product concept to be CE-marked during 2018.

By using Helge, it is possible to instantly determine whether a sample has been hemolyzed and needs retaking, or if it can be sent to the laboratory for analysis. This patented product ensures most hemolyzed blood samples are detected at the point of care, allowing an immediate retake to obtain a high quality sample that can be sent for analysis.



Digital reader

A new, digital reader is under development and estimated to be completed during 2017 for CE-marking during 2018. The reader has three main purposes:

- (1) to alleviate the use of the point of care test by removing the subjective evaluation of the test in its current version.
- (2) to enable lower manufacturing costs of the disposable test.
- (3) to increase durability and simplify packaging of the disposable test by removing components used for manual reading of test results.

hemCheck's goals during 2017-2018

- Continued user tests of the disposable product for documentation of user friendliness and test performance
 - Completion of the digital reader and verifying user tests
 - CE-marking of the product concept (disposable test and digital reader)
-

